Related Experiment Videos
Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma
T J Hieken1, S G Ronan, M Farolan
1Department of Surgical Oncology, University of Illinois at Chicago, USA.
Cancer
|February 19, 1999
Summary
Integrin expression, specifically beta3 integrin, is a significant prognostic marker for intermediate-thickness melanoma, predicting patient survival and metastasis patterns. This finding aids in melanoma prognosis beyond traditional criteria.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Morphologic criteria alone have limitations in predicting prognosis for intermediate-thickness primary melanoma.
- Research is ongoing to identify additional prognostic markers for melanoma.
Purpose of the Study:
- To investigate the prognostic significance of p53, beta1 integrin, and beta3 integrin expression in intermediate-thickness malignant melanoma.
- To correlate integrin expression with patient survival and metastasis patterns.
Main Methods:
- Analysis of p53, beta1 integrin, and beta3 integrin expression in primary tumors from 111 melanoma patients.
- Statistical analysis to determine the prognostic value of these markers and other histopathologic features.
Main Results:
- Beta3 integrin expression was significantly associated with increased mortality (45% vs. 8%).
- Beta3 integrin predicted lung metastases, while beta1 integrin correlated with lymph node involvement.
- Other significant prognostic factors included lymph node status, Clark's level, thickness, and mitotic rate.
Conclusions:
- Integrin expression (beta1 and beta3) serves as a valuable prognostic marker for intermediate-thickness melanoma.
- These markers may help predict the site of metastasis, offering clinical utility.
- Further research is warranted to explore the clinical applications of integrin expression in melanoma management.